Program
giredestrant
Also written as “Giredestrant”, “GDC-9545” and “[14C]-GDC-9545”.
Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms · Ovarian Neoplasms, led by Hoffmann-La Roche.
Drug pageGiredestrant: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 1712 open or running | phase 3since Sep 8, 2020 | Nov 1, 2017 | Jul 31, 2027phase 1 · NCT03332797 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6171 giredestrant
, phase 4, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 4 earlier studies, Nov 1, 2017 to Jun 16, 2020.
- Dec 9, 2019Named giredestrantINNProposed as its International Nonproprietary Name in WHO's List 122 · before, GDC-9545
- Sep 8, 2020Phase 3 study in Breast NeoplasmsNCT04546009 · 992 enrolled · United States, Argentina, Australia and more
- Sep 30, 2020Phase 2 study in Breast NeoplasmsNCT04576455 · 303 enrolled · United States, Argentina, Australia and more
- Dec 17, 2020Phase 1 study in Healthy VolunteersNCT04680273 · 16 enrolled · United Kingdom
- Mar 15, 2021Phase 2 study in Neoplasm MetastasisNCT04802759 · 316 planned · United States, Australia, Israel and more
- Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more
- Jul 5, 2021Phase 3 study in Breast NeoplasmsNCT04961996 · 4,170 enrolled · United States, Argentina, Australia and more
- Mar 23, 20222 phase 3 studies in Breast NeoplasmsNCT05306340, NCT05296798
- Nov 21, 2022Phase 2 study in Endometrial NeoplasmsNCT05634499 · 33 enrolled · United States, Canada, Italy and more
- Sep 26, 2023Phase 3 study in Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06065748 · 1,050 enrolled · United States, Argentina, Australia and more
- Jun 26, 2025Phase 2 study in Breast NeoplasmsNCT07054190 · 120 planned · United States, Argentina, Brazil and more
- Apr 15, 2026Phase 3 study in Breast NeoplasmsNCT07541079 · 300 planned · United States
- Sep 15, 2026Phase 3 study in Breast NeoplasmsNCT07827573 · 1,500 planned · United States, Canada
- Sep 29, 2026Primary completion moved from 2027-10-31 to 2027-12-31Date moved laterphase 3 · +2 months · NCT05296798
- Oct 2, 2026Primary completion moved from 2027-12-31 to 2028-06-15Date moved laterphase 3 · +5 months · NCT05296798
Ahead
- Jul 31, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT07054190
- Jul 31, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT03332797
- Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT04931342
- Apr 20, 2028Primary completion: phase 3 study in Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06065748
TargetBeta
“An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevent…”NCIt, read by Claude
“An orally available selective estrogen receptor degrader/downregulator (SERD), ”NCIt, by rule
“Estrogen receptor alpha degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07827573Breast Neoplasms · United States, Canada | 3 | Recruiting | Nov 30, 2028 | 1,500 |
| NCT07541079Breast Neoplasms · United States | 3 | Recruiting | Jun 30, 2032 | 300 |
| NCT07054190Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Jul 31, 2027 | 120 |
| NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 20, 2028 | 1,050 |
| NCT05634499Endometrial Neoplasms · United States, Canada, Italy and more | 2 | Completed | Aug 25, 2026 | 33 |
| NCT05306340Breast Neoplasms · United States, Argentina, Germany and more | 3 | Active, not recruiting | Jul 16, 2025 | 373 |
| NCT05296798Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Jun 15, 2028 | 922 |
| NCT04961996Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 8, 2025 | 4,170 |
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 28, 2028 | 176 |
| NCT04802759Neoplasm Metastasis · United States, Australia, Israel and more | 2 | Recruiting | May 30, 2029 | 316 |
| NCT04680273Healthy Volunteers · United Kingdom | 1 | Completed | Apr 12, 2021 | 16 |
| NCT04576455Breast Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Feb 18, 2022 | 303 |
| NCT04546009Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 30, 2026 | 992 |
| NCT04436744Breast Neoplasms · United States, Australia, Brazil and more | 2 | Completed | Jul 6, 2021 | 221 |
| NCT04274075Healthy Volunteers · United States | 1 | Completed | Apr 16, 2020 | 18 |
| NCT03916744Breast Neoplasms · United States, Australia, Belgium and more | 1 | Completed | May 25, 2021 | 75 |
| NCT03332797Breast Neoplasms · United States, Australia, South Korea and more | 1 | Active, not recruiting | Jul 31, 2027 | 181 |
How it is read
Names in the registry
- “Giredestrant”, 14 entries
- “GDC-9545”, 1 entry
- “[14C]-GDC-9545”, 1 entry
- “GDC-9545 Solution for Infusion”, 1 entry
- “GDC-9545/F12 Capsule”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 12 studies
- Neoplasm Metastasis, 1 study
- Endometrial Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.